$CKPT
Checkpoint Therapeutics, Inc.

2019 Q4 Form 10-K Financial Statement

#000110465921035291 Filed on March 12, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $30.00K $1.710M $3.030M
YoY Change -99.01% -51.28% 818.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.150M $7.230M $1.500M
YoY Change 43.33% 9.71% 10.29%
% of Gross Profit
Research & Development $6.730M $19.33M $13.42M
YoY Change -49.85% -42.58% 172.76%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.880M $26.56M $14.92M
YoY Change -40.49% -34.01% 137.97%
Operating Profit -$24.85M
YoY Change -32.36%
Interest Expense $30.00K $140.0K $50.00K
YoY Change -40.0% -6.67% 150.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $136.0K $230.0K
YoY Change -100.0% -63.54%
Pretax Income -$8.830M -$24.71M -$11.62M
YoY Change -24.01% -32.06% 96.28%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.830M -$24.71M -$11.62M
YoY Change -24.0% -32.04% 96.33%
Net Earnings / Revenue -29433.33% -1445.26% -383.47%
Basic Earnings Per Share
Diluted Earnings Per Share -$211.9K -$700.0K -$373.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.08M $26.08M $22.00M
YoY Change 18.55% 18.55% 14.4%
Cash & Equivalents $26.08M $26.08M $22.00M
Short-Term Investments
Other Short-Term Assets $26.00K $860.0K $1.532M
YoY Change -98.3% -37.23% 362.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.97M $26.97M $24.90M
YoY Change 8.3% 8.31% 16.28%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $26.97M $26.97M $24.90M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $26.97M $26.97M $24.90M
YoY Change 8.3% 8.31% 16.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.079M $3.080M $9.750M
YoY Change -68.42% -68.41% 167.49%
Accrued Expenses $410.0K $410.0K
YoY Change -6.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.119M $8.120M $13.09M
YoY Change -37.99% -37.97% 105.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.119M $8.120M $13.09M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $8.119M $8.120M $13.09M
YoY Change -37.99% -37.97% 105.48%
SHAREHOLDERS EQUITY
Retained Earnings -$120.1M -$95.40M
YoY Change 25.91% 61.61%
Common Stock $5.000K $3.000K
YoY Change 66.67% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.85M $18.85M $11.81M
YoY Change
Total Liabilities & Shareholders Equity $26.97M $26.97M $24.90M
YoY Change 8.3% 8.31% 16.28%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$8.830M -$24.71M -$11.62M
YoY Change -24.0% -32.04% 96.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.730M -$21.37M -$7.610M
YoY Change -37.84% -17.17% 81.62%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.75M 25.46M 0.000
YoY Change -10.92%
NET CHANGE
Cash From Operating Activities -4.730M -21.37M -7.610M
Cash From Investing Activities 0.000
Cash From Financing Activities 17.75M 25.46M 0.000
Net Change In Cash 13.02M 4.082M -7.610M
YoY Change -271.09% 47.36% 81.62%
FREE CASH FLOW
Cash From Operating Activities -$4.730M -$21.37M -$7.610M
Capital Expenditures $0.00
Free Cash Flow -$7.610M
YoY Change 81.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
12767000
CY2019 ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
8011000
CY2020 ckpt Issuance Of Common Shares At The Market Offering
IssuanceOfCommonSharesAtTheMarketOffering
-374000
CY2019 ckpt Issuance Of Common Shares At The Market Offering
IssuanceOfCommonSharesAtTheMarketOffering
-198000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001651407
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Registrant Name
EntityRegistrantName
Checkpoint Therapeutics, Inc.
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47004764
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62420439
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1742449
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-38128
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2568632
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
9th Floor
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
CY2020 dei City Area Code
CityAreaCode
781
CY2020 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per
CY2020 dei Trading Symbol
TradingSymbol
CKPT
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
80720490
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40772000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26077000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1804000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
863000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
20000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42596000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
26966000
CY2020Q4 us-gaap Assets
Assets
42596000
CY2019Q4 us-gaap Assets
Assets
26966000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6367000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7257000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
850000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
862000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7217000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8119000
CY2020Q4 us-gaap Liabilities
Liabilities
7217000
CY2019Q4 us-gaap Liabilities
Liabilities
8119000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62420439
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47004764
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120111000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18847000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42596000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26966000
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1069000
CY2019 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1708000
CY2019Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1459305
CY2020Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
4617000
CY2019Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
2510000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
173947000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
136442000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143192000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16352000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19325000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7918000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7233000
CY2020 us-gaap Operating Expenses
OperatingExpenses
24270000
CY2019 us-gaap Operating Expenses
OperatingExpenses
26558000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-23201000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-24850000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
120000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
136000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
120000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
136000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23081000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-24714000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55830582
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35303955
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11806000
CY2019 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
7813000
CY2019 ckpt Stock Issued During Period Value Common Shares For Public Offering
StockIssuedDuringPeriodValueCommonSharesForPublicOffering
17573000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3121000
CY2019 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
738000
CY2019 ckpt Stock Issued During Period Value Issuable For Services
StockIssuedDuringPeriodValueIssuableForServices
2510000
CY2019 ckpt Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
0
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-24714000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18847000
CY2020 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
12393000
CY2020 ckpt Stock Issued During Period Value Common Shares For Public Offering
StockIssuedDuringPeriodValueCommonSharesForPublicOffering
18909000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2780000
CY2020 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
901000
CY2020 ckpt Stock Issued During Period Value Issuable For Services
StockIssuedDuringPeriodValueIssuableForServices
4617000
CY2020 ckpt Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
13000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23081000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23081000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-24714000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2780000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3121000
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
901000
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
738000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31246000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25455000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14695000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4082000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26077000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21995000
CY2020 ckpt Common Shares Issuable Under Founder Agreement
CommonSharesIssuableUnderFounderAgreement
4617000
CY2019 ckpt Common Shares Issuable Under Founder Agreement
CommonSharesIssuableUnderFounderAgreement
2510000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
941000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-509000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-6000
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1506000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-833000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5043000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40772000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26077000
CY2020 us-gaap Stock Issued1
StockIssued1
2510000
CY2019 us-gaap Stock Issued1
StockIssued1
1748000
CY2020 ckpt Stock Issued Under Public Offering Costs Not Paid
StockIssuedUnderPublicOfferingCostsNotPaid
0
CY2019 ckpt Stock Issued Under Public Offering Costs Not Paid
StockIssuedUnderPublicOfferingCostsNotPaid
69000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16551000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21373000
CY2020 ckpt Proceeds From Issuance Of Common Stock Public Offering
ProceedsFromIssuanceOfCommonStockPublicOffering
20500000
CY2019 ckpt Proceeds From Issuance Of Common Stock Public Offering
ProceedsFromIssuanceOfCommonStockPublicOffering
19560000
CY2020 ckpt Issuance Of Common Shares Public Offering
IssuanceOfCommonSharesPublicOffering
-1660000
CY2019 ckpt Issuance Of Common Shares Public Offering
IssuanceOfCommonSharesPublicOffering
-1918000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2015Q1 ckpt Equity Method Investment Annual Equity Fee Percentage.
EquityMethodInvestmentAnnualEquityFeePercentage.
0.025
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4147411
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7671286
CY2020Q2 ckpt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
35000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8000000.0
CY2020 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
12400000
CY2020Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2020Q4 ckpt Shelf Registration Statement Remaining Authorized Securities
ShelfRegistrationStatementRemainingAuthorizedSecurities
83600000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2800000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0065
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0102
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0177
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0272
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.0127
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0460
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9984
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0379
CY2020 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2780000
CY2019 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3121000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2020 ckpt Effective Income Tax Rate Reconciliation Change In State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatePercent
-0.01
CY2019 ckpt Effective Income Tax Rate Reconciliation Change In State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatePercent
0.02
CY2020 ckpt Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
0.01
CY2019 ckpt Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.24
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.27
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27537000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23051000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2191000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2057000
CY2020Q4 ckpt Deferred Tax Assets Amortization Of License
DeferredTaxAssetsAmortizationOfLicense
5560000
CY2019Q4 ckpt Deferred Tax Assets Amortization Of License
DeferredTaxAssetsAmortizationOfLicense
4878000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
178000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
184000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1781000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1532000
CY2020Q4 ckpt Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
28000
CY2019Q4 ckpt Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
31000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37275000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
31733000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37275000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31733000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37300000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31700000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3438000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3079000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
535000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
414000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2009000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3496000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
385000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
268000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6367000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7257000

Files In Submission

Name View Source Status
0001104659-21-035291-index-headers.html Edgar Link pending
0001104659-21-035291-index.html Edgar Link pending
0001104659-21-035291.txt Edgar Link pending
0001104659-21-035291-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20201230.xsd Edgar Link pending
tmb-20201230x10k.htm Edgar Link pending
tmb-20201230x10k_htm.xml Edgar Link completed
tmb-20201230xex23d1.htm Edgar Link pending
tmb-20201230xex31d1.htm Edgar Link pending
tmb-20201230xex31d2.htm Edgar Link pending
tmb-20201230xex32d1.htm Edgar Link pending
tmb-20201230xex32d2.htm Edgar Link pending
tmb-20201230xex4d3.htm Edgar Link pending
tmb-20201230_cal.xml Edgar Link unprocessable
tmb-20201230_def.xml Edgar Link unprocessable
tmb-20201230_lab.xml Edgar Link unprocessable
tmb-20201230_pre.xml Edgar Link unprocessable